Home > Compound List > Product Information
Cabergoline_Molecular_structure_CAS_81409-90-7)
Click picture or here to close

Cabergoline

Catalog No. C0246 Name Sigma Aldrich
CAS Number 81409-90-7 Website http://www.sigmaaldrich.com
M. F. C26H37N5O2 Telephone 1-800-521-8956
M. W. 451.60428 Fax
Purity ≥98% (HPLC) Email
Storage Chembase ID: 133

SYNONYMS

IUPAC name
1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea
IUPAC Traditional name
cabergoline
Synonyms
Dostinex
1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea
Cabaser
1-Ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′β-carbonyl)urea
FCE-21336

DATABASE IDS

MDL Number MFCD00867887
CAS Number 81409-90-7

PROPERTIES

Empirical Formula (Hill Notation) C26H37N5O2
Purity ≥98% (HPLC)
Apperance powder
Solubility DMSO: ≥10 mg/mL
GHS Pictograms GHS07
GHS Signal Word Warning
GHS Hazard statements H302-H315-H319-H335
European Hazard Symbols Irritant Irritant (Xi)
MSDS Link Download
GHS Precautionary statements P261-P305 + P351 + P338
Risk Statements 36/37/38
RTECS KE6167600
Safety Statements 26-36/37
Storage Temperature 2-8°C
German water hazard class 3

DETAILS

Description (English)
Biochem/physiol Actions
Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).
Description (简体中文)
Biochem/physiol Actions
Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).

REFERENCES